Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

Feb 19 2020

• By Cathy Kelly

Macro photo of tooth wheel mechanism with ENGAGEMENT concept letters — ICER Interested In More Engagement With FDA

Related Content

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

Jan 26 2020

FDA Drug Reviews Could Benefit From Insights Into What Payers Want, OND Chief Says

Jan 14 2020

Patient-Focused Drug Development: US FDA 'Needs To Be Brave,' Tell Sponsors What Works Best

Oct 29 2018

Patient-Focused Drug Development: US FDA’s Guidance Development Effort Passes The Mid-Point

Feb 09 2020

ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years

Feb 06 2020

Related Companies

Allergan plc

Eli Lilly and Company

Biohaven Pharmaceutical Holding Company Ltd.

Additional Topics

United States Health Technology Assessment Reimbursement Policy Pricing Debate BioPharmaceutical

More from Health Technology Assessment

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window